Scarica l'app Stockscreener
0.5101
0.23%
-0.0012
Dopo l'orario di chiusura:
.52
0.0099
+1.94%
Precedente Chiudi:
$0.5113
Aprire:
$0.5113
Volume 24 ore:
431.17K
Relative Volume:
0.92
Capitalizzazione di mercato:
$2.68M
Reddito:
$31.80M
Utile/perdita netta:
$-58.49M
Rapporto P/E:
-0.7761
EPS:
-0.6573
Flusso di cassa netto:
$-17.58M
1 W Prestazione:
-3.75%
1M Prestazione:
-12.08%
6M Prestazione:
-30.75%
1 anno Prestazione:
-36.16%
Intervallo 1D:
$0.50
$0.533
Intervallo di 1 settimana:
$0.4618
$0.575
Portata 52W:
$0.4618
$1.18
Xilio Therapeutics Inc Stock (XLO) Company Profile
Nome
Xilio Therapeutics Inc
Settore
Industria
Telefono
617-833-1027
Indirizzo
828 WINTER STREET, WALTHAM
Compare XLO vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
XLO
Xilio Therapeutics Inc
|
0.5101 | 2.68M | 31.80M | -58.49M | -17.58M | -0.6573 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Xilio Therapeutics Inc Stock (XLO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-06 | Iniziato | Leerink Partners | Outperform |
| 2022-12-21 | Iniziato | Chardan Capital Markets | Buy |
| 2022-01-10 | Iniziato | H.C. Wainwright | Buy |
| 2021-11-16 | Iniziato | Cowen | Outperform |
| 2021-11-16 | Iniziato | Guggenheim | Buy |
| 2021-11-16 | Iniziato | Morgan Stanley | Overweight |
| 2021-11-16 | Iniziato | Raymond James | Outperform |
Mostra tutto
Xilio Therapeutics Inc Borsa (XLO) Ultime notizie
Trading Halt: Halted at 7:50:00 p.m. ETTrading Halt: Halt News PendingXilio Therapeutics (NASDAQ:XLO) - Benzinga
Xilio Therapeutics implements 1-for-14 reverse stock split By Investing.com - Investing.com India
Xilio Therapeutics Announces 1-for-14 Reverse Stock Split - Sahm
Published on: 2026-03-13 07:54:21 - baoquankhu1.vn
Xilio Therapeutics implements 1-for-14 reverse stock split - Investing.com South Africa
Cancer biotech Xilio enacts 1-for-14 reverse split to regain Nasdaq compliance - Stock Titan
Xilio Therapeutics Advances Masked Immuno-Oncology Therapies with Robust Pipeline, Strategic Partnerships, and Strong Financials (2026 Update) - Minichart
Xilio Therapeutics Updates Investor Presentation on I-O Strategy - TipRanks
Xilio Therapeutics posts investor presentation highlighting pipeline, $137.5M cash and upcoming INDs - TradingView
XLO SEC FilingsXilio Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Can Xilio Therapeutics Inc expand into new marketsJuly 2025 Gainers & Reliable Entry Point Trade Alerts - baoquankhu1.vn
Institution Moves: How sustainable is Xilio Therapeutics Inc. stock dividend payout2025 Market WrapUp & Free Expert Verified Stock Movement Alerts - Naître et grandir
Chipmakers Recap: Is Xilio Therapeutics Inc benefiting from innovation trendsJuly 2025 Trends & Smart Money Movement Tracker - baoquankhu1.vn
Xilio Therapeutics Inc expected to post a loss of 12 cents a shareEarnings Preview - TradingView
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
XLO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Press Release: Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bitget
Xilio Therapeutics to Present at the Leerink Partners Global Healthcare Conference - The Manila Times
Xilio Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
XLO PE Ratio & Valuation, Is XLO Overvalued - Intellectia AI
Is Xilio Therapeutics Inc. benefiting from innovation trendsPortfolio Performance Report & Free Technical Confirmation Trade Alerts - mfd.ru
Xilio Therapeutics Shareholders Approve Flexible Reverse Stock Split - The Globe and Mail
Xilio Therapeutics (NASDAQ: XLO) gains stockholder OK for reverse stock split range - Stock Titan
Entry Recap: Why is Xilio Therapeutics Inc stock going down2025 Top Gainers & Capital Efficient Trading Techniques - baoquankhu1.vn
Will Xilio Therapeutics Inc. stock reach Wall Street targetsWeekly Investment Report & Fast Gaining Stock Strategy Reports - mfd.ru
Bain Capital Life Sciences reports 9.99% Xilio (XLO) stake capped by blocker - Stock Titan
What is the long term forecast for Xilio Therapeutics Inc. stockEarnings Overview Report & High Yield Equity Trading Tips - mfd.ru
Frazier Life Sciences funds detail Xilio Therapeutics (XLO) ownership and warrants - Stock Titan
What is the Moat Score of Xilio Therapeutics Inc.July 2025 Opening Moves & Daily Volume Surge Trade Alerts - mfd.ru
Xilio Therapeutics Prices Pre-Funded Warrant Offering Financing - TipRanks
Xilio Therapeutics Signs Underwriting Agreement With Leerink Partners - TradingView
Xilio Therapeutics (NASDAQ: XLO) raises ~$40M via 74.8M pre-funded warrants - Stock Titan
Gilead discloses 19.9% stake in Xilio Therapeutics (XLO) ownership filing - Stock Titan
Xilio Therapeutics Launches Pre-Funded Warrant Offering - Intellectia AI
Xilio Therapeutics Prices $40M Underwritten Offering - National Today
Xilio Therapeutics Prices Pre-Funded Warrant Offering - Intellectia AI
Xilio Therapeutics Announces Pricing of Underwritten Offering - Yahoo Finance
Xilio Therapeutics announces pricing of underwritten offering - marketscreener.com
Xilio Therapeutics Announces Pricing Of Underwritten Offering - TradingView
Xilio Therapeutics Announces Pricing of $40 Million Underwritten Offering of Pre-Funded Warrants - Quiver Quantitative
Cancer drug developer Xilio raises $40M in warrant deal - Stock Titan
Can Xilio Therapeutics Inc. expand into new marketsDollar Strength & Entry Point Confirmation Signals - mfd.ru
Xilio (XLO) cuts Leerink-led stock offering capacity to $9.5M - Stock Titan
Xilio Therapeutics (NASDAQ:XLO) Shares Up 0.9% – Still a Buy? - Defense World
Earnings Risk: Can Xilio Therapeutics Inc deliver alphaM&A Rumor & Verified Short-Term Trading Plans - baoquankhu1.vn
Aug PostEarnings: Can Xilio Therapeutics Inc deliver alphaWeekly Investment Recap & Weekly Stock Breakout Alerts - baoquankhu1.vn
Growth Recap: How cyclical is Xilio Therapeutics Incs revenue streamCPI Data & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Sell Signal: What is AAMUs market position2025 Dividend Review & High Win Rate Trade Tips - baoquankhu1.vn
Highs Report: What is Espey Mfg Electronics Corps market positionJuly 2025 Trends & Technical Pattern Recognition Alerts - baoquankhu1.vn
Xilio Therapeutics Inc Azioni (XLO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):